Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Generic Pharma

Impax Laboratories Inc

+ Add to Watchlist

IPXL:US

49.9800 USD 1.2800 2.50%

As of 20:10:00 ET on 04/17/2015.

Snapshot for Impax Laboratories Inc (IPXL)

Open: 49.4100 Day's Range: 49.1100 - 50.2400 Volume: 1,134,276
Previous Close: 51.2600 52wk Range: 22.1200 - 52.1000 1-Yr Rtn: +108.95%

Stock Chart for IPXL

No chart data available.
  • IPXL:US 49.9800
  • 1D
  • 1M
  • 1Y
51.2600
Interactive IPXL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for IPXL

Current P/E Ratio (ttm) 45.4558
Estimated P/E(12/2015) 31.5929
Relative P/E vs. SPX 2.4748
Earnings Per Share (USD) (ttm) 1.0995
Est. EPS (USD) (12/2015) 1.5820
Est. PEG Ratio 1.2420
Market Cap (M USD) 3,593.42
Shares Outstanding (M) 71.90
30 Day Average Volume 716,241
Price/Book (mrq) 4.0095
Price/Sale (ttm) 5.7175
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/11/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for IPXL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for IPXL

Impax Laboratories, Inc. develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. The Company specializes in the development of niche and controlled release generics, as well as the development of branded products.

George Frederick Wilkinson "Fred"President/CEOMichael J NestorPres:Impax Pharmaceuticals
Mark A SchlossbergSenior VP/Secy/General CounselBryan M ReasonsSenior VP:Finance/CFO
More Company Profile & Key Executives for IPXL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil